{"id":46114,"date":"2025-11-08T10:27:11","date_gmt":"2025-11-08T02:27:11","guid":{"rendered":"https:\/\/flcube.com\/?p=46114"},"modified":"2025-11-08T10:27:12","modified_gmt":"2025-11-08T02:27:12","slug":"humanwell-healthcare-secures-nmpa-approval-to-launch-first-fixed%e2%80%91dose-combination-for-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46114","title":{"rendered":"Humanwell Healthcare Secures NMPA Approval to Launch First Fixed\u2011Dose Combination for Pulmonary Arterial Hypertension"},"content":{"rendered":"\n

Humanwell Healthcare (Group) Co., Ltd<\/strong> (SHA: 600079<\/a>) announced that its investigational compound HWH217<\/strong> has received clearance from the National Medical Products Administration (NMPA)<\/strong> to commence Phase\u202fI\/II clinical trials<\/strong> in China. The drug targets Pulmonary Arterial Hypertension (PAH, WHO Group\u202f1)<\/strong> \u2013 a rare, progressive disease with limited therapeutic options in the Chinese market.<\/p>\n\n\n\n

What Is HWH217?<\/h2>\n\n\n\n
Attribute<\/th>Details<\/th><\/tr><\/thead>
Category<\/strong><\/td>2.3 chemical drug (new molecular entity)<\/td><\/tr>
Formulation<\/strong><\/td>Fixed\u2011dose combination (FDC) of two approved active ingredients<\/strong> in a single tablet<\/td><\/tr>
Indication<\/strong><\/td>Treatment of Pulmonary Arterial Hypertension (WHO\u202fGroup\u202f1)<\/strong><\/td><\/tr>
Regulatory status<\/strong><\/td>NMPA clinical\u2011trial approval<\/strong> as of 7\u202fNov\u202f2025<\/td><\/tr>
Market novelty<\/strong><\/td>First FDC<\/strong> for PAH approved for clinical testing in China; no comparable product currently on the Chinese market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical\u2011Trial Outlook<\/h2>\n\n\n\n